Eli Lilly is opening a limited early-access pathway for its experimental weight loss drug, retatrutide, offering hope to a small group of patients with severe obesity who have exhausted other options. The move comes ahead of Food and Drug Administration approval and follows growing demand from physicians after the company granted a single patient exclusive access to the therapy earlier this year.
Under the new program, eligible adults must be 18 or older, have treatment-resistant obesity, and suffer from at least two serious or life-threatening obesity-related complications. They must also be unable to enroll in ongoing clinical trials or use comparable treatments. A company spokesperson said the decision aligns with FDA guidance and is medically appropriate for patients who meet these strict criteria.
Retatrutide represents the next generation of GLP-1 therapies. Unlike existing blockbusters such as Zepbound and Mounjaro, which are dual agonists, retatrutide is a first-in-class triple agonist. It mimics three hormones that regulate appetite and metabolism, offering a more powerful approach than single-agonist drugs like Wegovy or Ozempic.
Clinical trial data, announced by Eli Lilly in May but not yet peer-reviewed, showed striking results. Among 2,339 participants who were obese or overweight, those on the highest dose lost an average of 70 pounds, or 28.7% of their body weight, after 80 weeks. For patients with a body mass index over 35, the average loss reached 85 pounds, or 30.3%, after two years. That level of reduction is comparable to outcomes seen with gastric bypass surgery.
By comparison, trial participants taking Zepbound lost about 50 pounds over 72 weeks, while those on semaglutide, the active ingredient in Wegovy, lost roughly 33 pounds. The new drug also produced substantial relief from osteoarthritis knee pain, a secondary benefit that could broaden its appeal. Eli Lilly executives noted that patients with obesity and knee osteoarthritis often face restricted mobility and may eventually need joint replacement, making retatrutide a potential option for addressing both weight and pain.
Side effects were more pronounced at higher doses, with nausea, vomiting, diarrhea, and constipation commonly reported. About 11% of participants on the highest dose dropped out due to these issues, a higher discontinuation rate than seen in earlier obesity drug trials.
Eli Lilly has not announced a timeline for seeking FDA approval, but the company has additional retatrutide trials planned this year. For patients who qualify, the early-access program offers a rare opportunity to receive a therapy that could redefine obesity treatment, especially for those with serious complications who have run out of standard options.